Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,079.89 +9.34 (+0.18%) Dow
38,495.41 -8.28 (-0.02%) Nasdaq
15,789.65 +93.01 (+0.59%) Bitcoin USD
66,128.43 -445.14 (-0.67%) CMC Crypto 200
1,427.78 +3.68 (+0.26%)
Verve Therapeutics, Inc. (VERV)
| Previous close | 6.88 |
| Open | 6.87 |
| Bid | 6.78 x 200 |
| Ask | 6.90 x 600 |
| Day's range | 6.73 - 6.92 |
| 52-week range | 6.42 - 21.42 |
| Volume | |
| Avg. volume | 1,296,977 |
| Market cap | 572.792M |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Verve Therapeutics Announces Updates on its PCSK9 Program
Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thrombocytopenia seen in the sixth participant enrolled in 0.45 mg/kg dose cohort Verve to prioritize development of VERVE-102, which uses a different LNP delivery system than VERVE-101; Clinical Trial Applications have been cleared by the U.K. MHRA and Health Canada; initiation of Heart-2 clin
- GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on March 28, 2024, the company granted equity awards to six new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 563
- GlobeNewswire
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of VERVE-101 in November 2023 Cash, Cash Equivalents and Marketable Securities of $624 Million with Cash Runway into Late 2026 BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course
